Home › NDC Lookup › RxCUI directory › RxCUI 2058924

Dacomitinib 30 MG Oral Tablet — RxCUI 2058924

RxNorm drug concept · Semantic clinical drug
RxCUI 2058924 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2058924
Official nameDacomitinib 30 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dacomitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Vizimpro is used to treat a specific type of advanced (metastatic) lung cancer called non-small cell lung cancer, or NSCLC. It's only for people whose tumors have a particular gene...
  • You take Vizimpro once a day by mouth as a tablet, and the good news is that food doesn't affect how well it works — so you can take it with or without a meal, whichever is more co...
  • How do I take this medication, and does it matter if I take it with food?
  • The most common ones are diarrhea, a skin rash (often acne-like), and nail infections — these happen in most people taking Vizimpro. Mouth sores, dry skin, hair thinning, decreased...
📖 Read our full Dacomitinib guide →

🕸️ Concept Web — How Dacomitinib 30 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Dacomitinib 30 MG Oral Tablet RxCUI 2058924

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Dacomitinib 2058849
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vizimpro 2058916
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Dacomitinib Oral Tablet 2058914
    • Dacomitinib Oral Product 2058911
    • Dacomitinib Pill 2058913
    • Dacomitinib Oral Tablet [Vizimpro] 2058919
    • Vizimpro Oral Product 2058920
    • Vizimpro Pill 2058921
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Dacomitinib 30 MG SCDC · 2058923
  • Dacomitinib Oral Tablet SCDF · 2058914
  • Dacomitinib Oral Product SCDG · 2058911
  • Dacomitinib Pill SCDG · 2058913

Brand-Name Concepts

  • Dacomitinib 30 MG Oral Tablet [Vizimpro] SBD · 2058926
  • Dacomitinib 30 MG [Vizimpro] SBDC · 2058925
  • Dacomitinib Oral Tablet [Vizimpro] SBDF · 2058919
  • Vizimpro Oral Product SBDG · 2058920
  • Vizimpro Pill SBDG · 2058921
  • Vizimpro BN · 2058916

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 2058924 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0197-30 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0069-0197-30) Vizimpro Pfizer Laboratories Div Pfizer Inc 2018-10-04
00069-1198-30 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0069-1198-30) Vizimpro Pfizer Laboratories Div Pfizer Inc 2018-10-04
00069-2299-30 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0069-2299-30) Vizimpro Pfizer Laboratories Div Pfizer Inc 2018-10-04
Observed labelers: Pfizer Laboratories Div Pfizer Inc (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.